Cargando…
Meta-Analysis and Gene Set Enrichment Relative to ER Status Reveal Elevated Activity of MYC and E2F in the “Basal” Breast Cancer Subgroup
BACKGROUND: Breast cancers lacking the estrogen receptor (ER) can be distinguished from other breast cancers on the basis of poor prognosis, high grade, distinctive histopathology and unique molecular signatures. These features further distinguish estrogen receptor negative (ER−) tumor subtypes, but...
Autores principales: | Alles, M. Chehani, Gardiner-Garden, Margaret, Nott, David J., Wang, Yixin, Foekens, John A., Sutherland, Robert L., Musgrove, Elizabeth A., Ormandy, Christopher J. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2650420/ https://www.ncbi.nlm.nih.gov/pubmed/19270750 http://dx.doi.org/10.1371/journal.pone.0004710 |
Ejemplares similares
-
Identification of Functional Networks of Estrogen- and c-Myc-Responsive Genes and Their Relationship to Response to Tamoxifen Therapy in Breast Cancer
por: Musgrove, Elizabeth A., et al.
Publicado: (2008) -
CDK inhibitors as potential breast cancer therapeutics: new evidence for enhanced efficacy in ER(+ )disease
por: Sutherland, Robert L, et al.
Publicado: (2009) -
Targeting cyclin-dependent kinase 1 (CDK1) but not CDK4/6 or CDK2 is selectively lethal to MYC-dependent human breast cancer cells
por: Kang, Jian, et al.
Publicado: (2014) -
Transcriptome analysis identifies pathways associated with enhanced maternal performance in QSi5 mice
por: Ramanathan, Palaniappan, et al.
Publicado: (2008) -
HER2-enriched subtype and novel molecular subgroups drive aromatase inhibitor resistance and an increased risk of relapse in early ER+/HER2+ breast cancer
por: Bergamino, Milana A., et al.
Publicado: (2022)